Apogee Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Apogee Therapeutics Common
APGE Stock   67.78  1.53  2.21%   
Apogee Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Apogee Therapeutics' valuation are provided below:
Market Capitalization
4.6 B
Earnings Share
(4.38)
There are over ninety-three available fundamental signals for Apogee Therapeutics Common, which can be analyzed over time and compared to other ratios. Investors should ensure to validate all of Apogee Therapeutics' prevailing performance against the performance from 2010 to 2026 to make sure the company is sustainable down the road. As of February 15, 2026, Market Cap is expected to decline to about 1.3 B. In addition to that, Enterprise Value is expected to decline to about 1.2 B
Check Apogee Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Apogee Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 42 M, Interest Income of 42 M or Depreciation And Amortization of 161.6 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 5.42. Apogee financial statements analysis is a perfect complement when working with Apogee Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Apogee Stock
Check out the analysis of Apogee Therapeutics Correlation against competitors.

Apogee Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets479.4 M867 M263.4 M
Slightly volatile
Other Current Liabilities18.7 M27.9 M12.5 M
Slightly volatile
Total Current Liabilities21.7 M32.8 M13.7 M
Slightly volatile
Total Stockholder Equity454.2 M824.3 M248.4 M
Slightly volatile
Accounts Payable1.3 M1.2 M659.5 K
Slightly volatile
Cash109.9 M127.6 M145.4 M
Slightly volatile
Cash And Short Term Investments391.6 M598.8 M228.3 M
Slightly volatile
Common Stock Shares Outstanding57.4 M63.5 M52.1 M
Slightly volatile
Liabilities And Stockholders Equity479.4 M867 M263.4 M
Slightly volatile
Other Current Assets5.3 M5 M1.1 M
Slightly volatile
Other Stockholder Equity653.5 M1.2 B393.8 M
Slightly volatile
Total Liabilities25.2 M42.7 M15.1 M
Slightly volatile
Net Invested Capital611.4 M1.2 B303.5 M
Slightly volatile
Total Current Assets396.1 M609.2 M230 M
Slightly volatile
Accumulated Other Comprehensive Income902.9 K823.5 K1.8 M
Slightly volatile
Net Working Capital374.4 M576.3 M216.3 M
Slightly volatile
Common Stock8559001.7 M
Slightly volatile
Short and Long Term Debt Total7.6 M13.6 M3.6 M
Slightly volatile
Non Currrent Assets Other494.4 K572.7 K422.3 K
Slightly volatile
Net Receivables3.3 M5.4 M1.8 M
Slightly volatile
Short Term Debt2.4 M3.7 M1.5 M
Slightly volatile

Apogee Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income42 M40 M7.5 M
Slightly volatile
Depreciation And Amortization161.6 K170.1 K26.2 M
Slightly volatile
Selling General Administrative59.2 M56.4 M13.4 M
Slightly volatile
Other Operating Expenses124.9 M249.4 M63.7 M
Slightly volatile
Research Development96.8 M193 M52.2 M
Slightly volatile
Total Operating Expenses124.9 M249.4 M63.7 M
Slightly volatile
Cost Of Revenue151.2 K170.1 K185.7 K
Slightly volatile

Apogee Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation28.2 M26.8 M6.6 M
Slightly volatile
Begin Period Cash Flow117 M106.7 M157.6 M
Slightly volatile
Issuance Of Capital Stock358.3 M567.5 M230.8 M
Slightly volatile
Total Cash From Financing Activities358.9 M569.4 M231 M
Slightly volatile
End Period Cash Flow110 M127.9 M145.5 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
PTB Ratio5.424.016.7695
Slightly volatile
Book Value Per Share6.2111.694.402
Slightly volatile
Capex To Depreciation4.885.495.9882
Slightly volatile
PB Ratio5.424.016.7695
Slightly volatile
Cash Per Share5.48.494.1233
Slightly volatile
Income Quality0.60.850.5087
Slightly volatile
Net Debt To EBITDA0.660.693.1254
Slightly volatile
Current Ratio14.1816.6915.6979
Slightly volatile
Tangible Book Value Per Share6.2111.694.402
Slightly volatile
Shareholders Equity Per Share6.2111.694.402
Slightly volatile
Debt To Equity0.00870.01490.0068
Slightly volatile
Capex Per Share0.00970.01880.0056
Slightly volatile
Graham Net Net5.077.943.8612
Slightly volatile
Interest Debt Per Share0.120.190.1713
Slightly volatile
Debt To Assets0.00830.01410.0064
Slightly volatile
Price Book Value Ratio5.424.016.7695
Slightly volatile
Ebt Per Ebit1.110.971.215
Slightly volatile
Company Equity Multiplier1.171.211.0824
Slightly volatile
Total Debt To Capitalization0.00860.01460.0067
Slightly volatile
Debt Equity Ratio0.00870.01490.0068
Slightly volatile
Quick Ratio14.1816.6915.6979
Slightly volatile
Net Income Per E B T0.80.90.9824
Slightly volatile
Cash Ratio9.525.7113.1649
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.80.910.9852
Slightly volatile
Price To Book Ratio5.424.016.7695
Slightly volatile
Debt Ratio0.00830.01410.0064
Slightly volatile
Price Fair Value5.424.016.7695
Slightly volatile

Apogee Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.3 B2.3 B1.3 B
Slightly volatile
Enterprise Value1.2 B2.1 B1.1 B
Slightly volatile

Apogee Fundamental Market Drivers

Apogee Upcoming Events

12th of February 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View
12th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Apogee Therapeutics Financial Statements

Apogee Therapeutics stakeholders use historical fundamental indicators, such as Apogee Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Apogee Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Apogee Therapeutics' assets and liabilities are reflected in the revenues and expenses on Apogee Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Apogee Therapeutics Common. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cost Of Revenue170.1 K151.2 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill
When determining whether Apogee Therapeutics is a strong investment it is important to analyze Apogee Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Apogee Therapeutics' future performance. For an informed investment choice regarding Apogee Stock, refer to the following important reports:
How To Invest In Apogee
Details
Is Apogee Stock a good investment?
Details
What is Apogee Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Apogee Therapeutics Correlation against competitors.
You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Will Biotechnology sector continue expanding? Could Apogee diversify its offerings? Factors like these will boost the valuation of Apogee Therapeutics. If investors know Apogee will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Apogee Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(4.38)
Return On Assets
(0.25)
Return On Equity
(0.38)
Investors evaluate Apogee Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Apogee Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Apogee Therapeutics' market price to deviate significantly from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Understanding that Apogee Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Apogee Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Apogee Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY